Ardelyx Gets FDA OK for Add-On Therapy for Kidney Disease Patients
By Ben Glickman
Ardelyx has received approval from the U.S. Food and Drug Administration for tenapanor, an add-on treatment for chronic kidney disease patients on dialysis.
The Waltham, Mass.-based biopharmaceutical company said its commercial launch of tenapanor, which goes by brand name Xphozah, was underway with product expected to become available next month.
The company said tenapanor is a phosphate absorption inhibitor which can be given to patients on dialysis with chronic kidney disease who don't have adequate response to phosphate binders or who have intolerance of phosphate binder therapy.
Ardelyx's application for Xphozah was previously rejected by the FDA, but the company appealed its rejection and its resubmission was accepted in May.
The FDA approval was based on a Phase 3 trial of Xphozah which met primary and key secondary endpoints.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
October 17, 2023 19:29 ET (23:29 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying
-
The 10 Best Companies to Invest in Now